@entity6 and outcome of community-acquired XXXX : a 10-year population-based cohort study.

@entity1 @entity7706 @entity6 @entity7964 @entity2333 @entity2259
OBJECTIVE: @entity1 with @entity6 may carry a higher case fatality of invasive @entity7706 compared with @entity7964 @entity1 due to decreased immunity, risk of metabolic derangement, or @entity2333 . We conducted a population-based cohort study to assess the impact of @entity6 on mortality within 90 days in @entity1 with @entity2259 . RESEARCH DESIGN AND METHODS: All @entity1 with community-acquired @entity2259 in North Jutland County, Denmark, from January 1992 to December 2001 were retrieved from the County @entity2259 Registry. Using civil registry numbers, @entity1 with @entity6 were identified by record linkage with the County Prescription Database (for antidiabetic drugs) and the County Hospital Discharge Registry. Mortality within 90 days was determined through the Central Population Registry. Mortality rates were compared for @entity6 and @entity7964 @entity1 and adjusted for sex, age, and comorbidity. RESULTS: Among 628 @entity1 aged >15 years with community-acquired @entity2259 , 63 (10.0%) had @entity6 . The @entity6 @entity1 were slightly older (median age 71.7 years) than the @entity7964 @entity1 (67.0 years), and the proportion of @entity1 with comorbidity was higher in the @entity6 group (59 vs. 46%). Mortality in @entity6 @entity1 compared with @entity7964 @entity1 was 11.1 vs. 16.5% after 30 days and 16.0 vs. 19.5% after 90 days, respectively. After adjustment for sex, age, and comorbidity, the mortality rate ratio for @entity6 @entity1 was 0.6 (95% CI 0.3-1.2) compared with the @entity7964 @entity1 . CONCLUSIONS: @entity6 @entity1 with community-acquired @entity2259 appear not to have a higher case fatality than @entity7964 @entity1 .
